Serum markers as an aid in the diagnosis of pulmonary fungal infections in AIDS patients

Autor(es)

Morsch Passos, Ana Isabela ; Dertkigil, Rachel Polo ; Ramos, Marcelo de Carvalho ; Busso-Lopes, Ariane Fidelis ; Tararan, Cibele ; Ribeiro, Erivan Olinda ; Schreiber, Angelica Zaninelli ; Trabasso, Plinio ; Resende, Mariangela Ribeiro ; Moretti, Maria Luiza

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Infectious Diseases; v. 21, n. 6, p. 7-pg., 2017-11-01.

Resumo

Introduction: The etiology of pulmonary infections in HIV patients is determined by several variables including geographic region and availability of antiretroviral therapy. Materials and methods: A cross-sectional prospective study was conducted from 2012 to 2016 to evaluate the occurrence of pulmonary fungal infection in HIV-patients hospitalized due to pulmonary infections. Patients' serums were tested for (1-3)-beta-D-Glugan, galactomannan, and lactate dehydrogenase. The association among the variables was analyzed by univariate and multivariate regression analysis. Results: 60 patients were included in the study. The patients were classified in three groups: Pneumocystis jirovecii pneumonia (19 patients), community-acquired pneumonia (18 patients), and other infections (23 patients). The overall mortality was 13.3%. The time since diagnosis of HIV infection was shorter in the pneumocystosis group (4.94 years; p = 0.001) than for the other two groups of patients. The multivariate analysis showed that higher (1-3)-beta-D-Glucan level (mean: 241 pg/mL) and lactate dehydrogenase (mean: 762 U/L) were associated with the diagnosis of pneumocystosis. Pneumocystosis was the aids-defining illness in 11 out of 16 newly diagnosed HIV-infected patients. Conclusion: In the era of antiretroviral therapy, PJP was still the most prevalent pulmonary infection and (1-3)-beta-D-Glucan and lactate dehydrogenase may be suitable markers to help diagnosing pneumocystosis in our HIV population. (C) 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. (AU)

• Processo FAPESP: 12/51158-0 - Aplicação de novas tecnologias para o aprimoramento do diagnóstico e manejo das infeccções fúngicas em pacientes com AIDS e outras condições imunodepressoras
• Beneficiário: Maria Luiza Moretti
• Modalidade de apoio: Auxílio à Pesquisa - Regular